NasdaqGS - Delayed Quote • USD
BeiGene, Ltd. (BGNE)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 12 | 10 |
| Avg. Estimate | -2.9 | -2.33 | -8.62 | -4.45 |
| Low Estimate | -3.13 | -2.81 | -13 | -8.16 |
| High Estimate | -2.43 | -2 | -0.93 | -0.53 |
| Year Ago EPS | -3.34 | -3.64 | -8.45 | -8.62 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 17 | 17 |
| Avg. Estimate | 675.59M | 755.4M | 3.06B | 3.9B |
| Low Estimate | 533.61M | 711.47M | 2.76B | 3.36B |
| High Estimate | 717.17M | 809M | 3.26B | 4.13B |
| Year Ago Sales | 449.43M | 519.08M | 2.46B | 3.06B |
| Sales Growth (year/est) | 50.30% | 45.50% | 24.40% | 27.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -3.77 | -2.81 | -3.11 | -3.96 |
| EPS Actual | -3.34 | -3.64 | 2.01 | -3.53 |
| Difference | 0.43 | -0.83 | 5.12 | 0.43 |
| Surprise % | 11.40% | -29.50% | 164.60% | 10.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -2.9 | -2.33 | -8.62 | -4.45 |
| 7 Days Ago | -2.86 | -2.33 | -8.59 | -4.42 |
| 30 Days Ago | -2.86 | -2.33 | -8.13 | -4.14 |
| 60 Days Ago | -2.64 | -2.48 | -9.12 | -2.43 |
| 90 Days Ago | -2.5 | -2.4 | -8.16 | -1.47 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | 1 | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | BGNE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 13.20% | -- | -- | 1.50% |
| Next Qtr. | 36.00% | -- | -- | 11.40% |
| Current Year | -2.00% | -- | -- | 5.20% |
| Next Year | 48.40% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 277.20% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | TD Cowen: Buy to Buy | 4/24/2024 |
| Maintains | B of A Securities: Neutral to Neutral | 4/8/2024 |
| Maintains | Bernstein: Market Perform to Market Perform | 3/27/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 3/20/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 3/19/2024 |
| Maintains | Guggenheim: Buy to Buy | 2/27/2024 |
Related Tickers
ZLAB Zai Lab Limited
15.66
+3.57%
LEGN Legend Biotech Corporation
45.17
-4.81%
ARGX argenx SE
375.00
-0.02%
ALNY Alnylam Pharmaceuticals, Inc.
143.80
-1.55%
INCY Incyte Corporation
51.74
+0.17%
GMAB Genmab A/S
28.47
-0.32%
MDGL Madrigal Pharmaceuticals, Inc.
204.65
-6.29%
BMRN BioMarin Pharmaceutical Inc.
91.20
-0.93%
JAZZ Jazz Pharmaceuticals plc
108.32
-1.23%
CYTK Cytokinetics, Incorporated
66.82
+1.91%